These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1830249)

  • 21. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
    Sternberg CN; Yagoda A; Scher H; Bosl G; Dershaw D; Rosado K; Houston C; Rosenbluth R; Vinciguerra V; Boselli B
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):753-4. PubMed ID: 2523810
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study.
    Cairncross JG; Eisenhauer EA; Macdonald DR; Rathbone MP; Moore MJ; Sawka CA; MacCormick RE; Kerr IG
    Can J Neurol Sci; 1990 Feb; 17(1):21-3. PubMed ID: 2138053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Studies of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
    Eisenhauer EA; Wierzbicki R; Knowling M; Bramwell VH; Quirt IC
    Ann Oncol; 1991 Oct; 2(9):689-90. PubMed ID: 1835885
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Dole GB; Rowinsky EK; Ettinger DS; Graham ML; McGuire WP; Donehower RC
    J Natl Cancer Inst; 1989 Jan; 81(2):124-30. PubMed ID: 2909752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
    Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
    J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.
    Casper ES; Christman KL; Schwartz GK; Johnson B; Brennan MF; Bertino JR
    Cancer; 1993 Aug; 72(3):766-70. PubMed ID: 8392904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phase I study of CI-898. CI-898 Study Group].
    Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
    Kraut EH; Bendetti J; Balcerzak SP; Doroshow JH
    Invest New Drugs; 1992 Nov; 10(4):347-9. PubMed ID: 1487411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
    Mattson K; Maasilta P; Tammilehto L; Holsti LR; Grove W
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):32-7. PubMed ID: 2835817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.
    Maroun J
    Semin Oncol; 1988 Apr; 15(2 Suppl 2):17-21. PubMed ID: 2835816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimetrexate: clinical development of a nonclassical antifolate.
    O'Dwyer PJ; DeLap RJ; King SA; Grillo-Lopez AJ; Hoth DF; Leyland-Jones B
    NCI Monogr; 1987; (5):105-9. PubMed ID: 2963228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
    Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
    Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
    Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimetrexate: a second generation folate antagonist in clinical trial.
    Lin JT; Bertino JR
    J Clin Oncol; 1987 Dec; 5(12):2032-40. PubMed ID: 2960788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.
    Schiesel JD; Carabasi M; Magill G; Casper E; Cheng E; Marks L; Feyzi J; Clendeninn NJ; Smalley RV
    Invest New Drugs; 1992 Jul; 10(2):97-8. PubMed ID: 1500271
    [No Abstract]   [Full Text] [Related]  

  • 37. Trimetrexate: predictors of severe or life-threatening toxic effects.
    Eisenhauer EA; Zee BC; Pater JL; Walsh WR
    J Natl Cancer Inst; 1988 Oct; 80(16):1318-22. PubMed ID: 2971818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding trimetrexate toxicity.
    Donehower RC
    J Natl Cancer Inst; 1988 Oct; 80(16):1268-9. PubMed ID: 2971816
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II trial of Baker's antifol in metastatic sarcoma.
    Thigpen JT; O'Bryan RM; Benjamin RS; Coltman CA
    Cancer Treat Rep; 1977 Nov; 61(8):1485-7. PubMed ID: 922752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of trimetrexate for the prevention of graft-versus-host disease.
    Appelbaum FR; Raff RF; Storb R; Deeg HJ; Graham TC; Sandmaier B; Schuening F
    Bone Marrow Transplant; 1989 Jul; 4(4):421-4. PubMed ID: 2528387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.